Evidence map›Paper›PMID 29354128›Full record

ArticleFrontiers in immunology2017

Prolonged Deleterious Influences of Chemotherapeutic Agent CPT-11 on Resident Peritoneal Macrophages and B1 Cells.

Wen-Jing Bai, Chen-Guang Li, Cheng-Cheng Zhang, Li-Hui Xu, Qiong-Zhen Zeng, Bo Hu, Zhou Hong, Xian-Hui He, Dong-Yun Ouyang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wen-Jing BaiDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Chen-Guang LiDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Cheng-Cheng ZhangDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Li-Hui XuDepartment of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Qiong-Zhen ZengDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Bo HuDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zhou HongDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Xian-Hui HeDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Dong-Yun OuyangDepartment of Immunobiology, College of Life Science and Technology, Jinan University, Guangzhou, China.
Jinan University · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CPT-11 is a first-line chemotherapeutic agent for the treatment of colorectal cancer in clinic. Previous studies including ours have demonstrated that CPT-11 is, however, toxic to the intestinal epithelium and resident peritoneal macrophages. By interacting with B1 cells, the resident peritoneal macrophages play critical roles in the maintenance of gastrointestinal homeostasis. It remains therefore elusive whether these peritoneal innate immune cells could be rebuilt spontaneously or artificially after being impaired by CPT-11 administration. In this study, we found that mouse resident peritoneal macrophages, namely the large peritoneal macrophages (LPMs) with a CD11b

Indexed as

adoptive transferCPT-11cytotoxicityperitoneal B1 cellsresident peritoneal macrophages

Identifiers

PMID29354128
PMCPMC5760539
OpenAlexW2781728313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.